PTCT
PTC Therapeutics Inc
63.70$
+0.3%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +50.5% | -5.6% | +7.1% | -3.9% | -7.4% | +55.7% | -0.8% | +0.4% | +9.6% | -1.0% | +13.3% | |
| – | +125.5% | -4.1% | +16.2% | -5.6% | +6.6% | +69.6% | -1.9% | -11.7% | +13.3% | -0.9% | +16.1% | |
| – | +259.7% | -7.7% | +19.4% | -19.7% | +48.2% | +89.8% | -31.3% | -33.9% | +46.4% | -15.3% | +25.9% | |
| – | +197.4% | +0.9% | +23.6% | -7.3% | +12.5% | +77.9% | -1.9% | -15.1% | +15.3% | -2.7% | +17.8% | |
| – | -3.0% | +22.9% | -5.3% | +6.9% | -20.7% | +32.8% | -6.8% | +3.5% | -10.6% | +21.1% | +8.7% | |
| – | -14.5% | -1.7% | +5.9% | +12.1% | -35.0% | -6.5% | +57.1% | +54.7% | +51.2% | -5.1% | +20.9% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -10.4% | -13.0% | 0.0% | +0.1% | -64.0% | -0.3% | +21.4% | +175.7% | -1.9% | -2.1% | +5.8% | |
| – | +40.6% | -1.1% | +7.9% | +0.0% | -3.2% | +1.4% | 0.0% | -1.5% | +10.9% | -1.8% | +12.0% | |
| – | +22.6% | -4.7% | +6.1% | +0.1% | -4.9% | +2.5% | +5.4% | +38.0% | +11.8% | -4.6% | -16.5% | |
| – | +1,369.3% | -92.1% | -3.1% | +4.7% | +1,518.5% | -93.9% | +3.5% | +1,660.8% | +94.5% | -47.9% | -75.9% | |
| – | -68.4% | +354.2% | -11.6% | -45.3% | +30.0% | -12.3% | +75.0% | +38.2% | +24.2% | -44.0% | +58.7% | |
| – | +232.2% | -85.1% | +0.1% | +0.1% | +639.9% | -86.5% | +0.1% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +1.3% | +0.3% | +0.3% | +0.4% | +11.9% | -9.5% | +11.5% | -7.4% | +2.3% | +11.5% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.